ID

36366

Beschreibung

Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02381314

Link

https://clinicaltrials.gov/show/NCT02381314

Stichworte

Versionen (1)
  1. 07.05.19 07.05.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

7. Mai 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Melanoma NCT02381314

Englisch

Eligibility Melanoma NCT02381314

1 Formulare  
  1. StudyEvent: Eligibility
    1. Eligibility Melanoma NCT02381314
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically-proven, unresectable, locally advanced or metastatic melanoma, scchn, or nsclc that express b7-h3.
Beschreibung

Melanoma Advanced Locally unresectable | Metastatic melanoma unresectable | Squamous cell carcinoma of the head and neck | Non-Small Cell Lung Carcinoma CD276 gene Expression

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0025202
UMLS CUI [1,2]
C0205179
UMLS CUI [1,3]
C1517927
UMLS CUI [1,4]
C1519810
UMLS CUI [2,1]
C0278883
UMLS CUI [2,2]
C1519810
UMLS CUI [3]
C1168401
UMLS CUI [4,1]
C0007131
UMLS CUI [4,2]
C1540293
UMLS CUI [4,3]
C0017262
melanoma that has progressed within 90 days with progression on a checkpoint inhibitor (e.g., anti-pd-l1, anti-pd-1, anti-ctla-4) as the most recent prior therapy
Beschreibung

Melanoma Progressive | Disease Progression | Other Coding | Anti-PD-L1 | Anti-PD1 | Anti-CTLA-4 | Prior Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0025202
UMLS CUI [1,2]
C0205329
UMLS CUI [2]
C0242656
UMLS CUI [3]
C3846158
UMLS CUI [4]
C4289971
UMLS CUI [5]
C4289970
UMLS CUI [6]
C4289973
UMLS CUI [7]
C1514463
schnn or nsclc that has progressed during or following 1 - 5 prior systemic regimens
Beschreibung

Squamous cell carcinoma of the head and neck | Non-Small Cell Lung Carcinoma | Disease Progression Following Systemic therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C1168401
UMLS CUI [2]
C0007131
UMLS CUI [3,1]
C0242656
UMLS CUI [3,2]
C0332282
UMLS CUI [3,3]
C1515119
measurable disease per recist 1.1 criteria
Beschreibung

Measurable Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C1513041
ecog performance status 0 or 1
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
acceptable laboratory parameters and adequate organ reserve.
Beschreibung

Laboratory Results Acceptable | Organ function Mass

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1254595
UMLS CUI [1,2]
C1879533
UMLS CUI [2,1]
C0678852
UMLS CUI [2,2]
C1306372
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
Beschreibung

CNS metastases Symptomatic | Exception CNS metastases Treated | Exception CNS metastases Asymptomatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0231220
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0686377
UMLS CUI [2,3]
C1522326
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0686377
UMLS CUI [3,3]
C0231221
patients with history of autoimmune disease with certain exceptions
Beschreibung

Autoimmune Disease

Datentyp

boolean

Alias
UMLS CUI [1]
C0004364
history of allogeneic bone marrow, stem cell, or solid organ transplant
Beschreibung

Allogeneic bone marrow transplantation | Stem cell transplant | Solid organ transplant

Datentyp

boolean

Alias
UMLS CUI [1]
C0149615
UMLS CUI [2]
C1504389
UMLS CUI [3]
C0730400
treatment with systemic cancer therapy or investigational therapy within 4 weeks; radiation within 2 weeks; trauma or major surgery within 4 weeks
Beschreibung

Cancer treatment Systemic | Therapy, Investigational | Therapeutic radiology procedure | Trauma Surgery | Major surgery

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
UMLS CUI [2]
C0949266
UMLS CUI [3]
C1522449
UMLS CUI [4,1]
C3714660
UMLS CUI [4,2]
C0543467
UMLS CUI [5]
C0679637
history of clinically-significant cardiovascular disease; gastrointestinal perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within 4 weeks;
Beschreibung

Cardiovascular Disease | Gastrointestinal perforation | Gastrointestinal Hemorrhage | Pancreatitis | Diverticulitis

Datentyp

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0151664
UMLS CUI [3]
C0017181
UMLS CUI [4]
C0030305
UMLS CUI [5]
C0012813
active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days; positive for human immunodeficiency virus or aids, hepatitis b or c.
Beschreibung

Virus Disease | Bacterial Infection | Systemic mycosis | Requirement Parenteral therapy | HIV Seropositivity | Hepatitis B positive | Hepatitis C positive

Datentyp

boolean

Alias
UMLS CUI [1]
C0042769
UMLS CUI [2]
C0004623
UMLS CUI [3]
C0553576
UMLS CUI [4,1]
C1514873
UMLS CUI [4,2]
C0259961
UMLS CUI [5]
C0019699
UMLS CUI [6]
C0856706
UMLS CUI [7]
C1112419
known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for mga271 or ipilimumab.
Beschreibung

Hypersensitivity Recombinant Proteins | Hypersensitivity Polysorbate 80 | Hypersensitivity Excipient MGA271 | Hypersensitivity Excipient Ipilimumab

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0034861
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0032601
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0015237
UMLS CUI [3,3]
C3273458
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0015237
UMLS CUI [4,3]
C1367202
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Melanoma NCT02381314

1 Formulare
  1. StudyEvent: Eligibility
    1. Eligibility Melanoma NCT02381314
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Melanoma Advanced Locally unresectable | Metastatic melanoma unresectable | Squamous cell carcinoma of the head and neck | Non-Small Cell Lung Carcinoma CD276 gene Expression
Item
histologically-proven, unresectable, locally advanced or metastatic melanoma, scchn, or nsclc that express b7-h3.
boolean
C0025202 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C1519810 (UMLS CUI [1,4])
C0278883 (UMLS CUI [2,1])
C1519810 (UMLS CUI [2,2])
C1168401 (UMLS CUI [3])
C0007131 (UMLS CUI [4,1])
C1540293 (UMLS CUI [4,2])
C0017262 (UMLS CUI [4,3])
Melanoma Progressive | Disease Progression | Other Coding | Anti-PD-L1 | Anti-PD1 | Anti-CTLA-4 | Prior Therapy
Item
melanoma that has progressed within 90 days with progression on a checkpoint inhibitor (e.g., anti-pd-l1, anti-pd-1, anti-ctla-4) as the most recent prior therapy
boolean
C0025202 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0242656 (UMLS CUI [2])
C3846158 (UMLS CUI [3])
C4289971 (UMLS CUI [4])
C4289970 (UMLS CUI [5])
C4289973 (UMLS CUI [6])
C1514463 (UMLS CUI [7])
Squamous cell carcinoma of the head and neck | Non-Small Cell Lung Carcinoma | Disease Progression Following Systemic therapy
Item
schnn or nsclc that has progressed during or following 1 - 5 prior systemic regimens
boolean
C1168401 (UMLS CUI [1])
C0007131 (UMLS CUI [2])
C0242656 (UMLS CUI [3,1])
C0332282 (UMLS CUI [3,2])
C1515119 (UMLS CUI [3,3])
Measurable Disease
Item
measurable disease per recist 1.1 criteria
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status 0 or 1
boolean
C1520224 (UMLS CUI [1])
Laboratory Results Acceptable | Organ function Mass
Item
acceptable laboratory parameters and adequate organ reserve.
boolean
C1254595 (UMLS CUI [1,1])
C1879533 (UMLS CUI [1,2])
C0678852 (UMLS CUI [2,1])
C1306372 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
CNS metastases Symptomatic | Exception CNS metastases Treated | Exception CNS metastases Asymptomatic
Item
patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
boolean
C0686377 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0686377 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0686377 (UMLS CUI [3,2])
C0231221 (UMLS CUI [3,3])
Autoimmune Disease
Item
patients with history of autoimmune disease with certain exceptions
boolean
C0004364 (UMLS CUI [1])
Allogeneic bone marrow transplantation | Stem cell transplant | Solid organ transplant
Item
history of allogeneic bone marrow, stem cell, or solid organ transplant
boolean
C0149615 (UMLS CUI [1])
C1504389 (UMLS CUI [2])
C0730400 (UMLS CUI [3])
Cancer treatment Systemic | Therapy, Investigational | Therapeutic radiology procedure | Trauma Surgery | Major surgery
Item
treatment with systemic cancer therapy or investigational therapy within 4 weeks; radiation within 2 weeks; trauma or major surgery within 4 weeks
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0949266 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C3714660 (UMLS CUI [4,1])
C0543467 (UMLS CUI [4,2])
C0679637 (UMLS CUI [5])
Cardiovascular Disease | Gastrointestinal perforation | Gastrointestinal Hemorrhage | Pancreatitis | Diverticulitis
Item
history of clinically-significant cardiovascular disease; gastrointestinal perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within 4 weeks;
boolean
C0007222 (UMLS CUI [1])
C0151664 (UMLS CUI [2])
C0017181 (UMLS CUI [3])
C0030305 (UMLS CUI [4])
C0012813 (UMLS CUI [5])
Virus Disease | Bacterial Infection | Systemic mycosis | Requirement Parenteral therapy | HIV Seropositivity | Hepatitis B positive | Hepatitis C positive
Item
active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days; positive for human immunodeficiency virus or aids, hepatitis b or c.
boolean
C0042769 (UMLS CUI [1])
C0004623 (UMLS CUI [2])
C0553576 (UMLS CUI [3])
C1514873 (UMLS CUI [4,1])
C0259961 (UMLS CUI [4,2])
C0019699 (UMLS CUI [5])
C0856706 (UMLS CUI [6])
C1112419 (UMLS CUI [7])
Hypersensitivity Recombinant Proteins | Hypersensitivity Polysorbate 80 | Hypersensitivity Excipient MGA271 | Hypersensitivity Excipient Ipilimumab
Item
known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for mga271 or ipilimumab.
boolean
C0020517 (UMLS CUI [1,1])
C0034861 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0032601 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0015237 (UMLS CUI [3,2])
C3273458 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0015237 (UMLS CUI [4,2])
C1367202 (UMLS CUI [4,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video